Mounjaro and Zepbound are the same drug. Both contain tirzepatide as their active ingredient, both are made by Eli Lilly, and both are delivered as a weekly injection under the skin. The difference is entirely about what they’re prescribed for: Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is FDA-approved for chronic weight management.
Same Drug, Different Labels
Tirzepatide is the molecule inside both medications. The FDA approved it first under the brand name Mounjaro for adults with type 2 diabetes, then later approved it as Zepbound specifically for chronic weight management. This isn’t unusual in medicine. Pharmaceutical companies often market the same active ingredient under separate brand names when it earns approval for a distinct condition. The two names exist so that doctors, pharmacists, and insurers can clearly distinguish which condition is being treated.
As of 2025, Mounjaro is approved for improving blood sugar control in adults and children aged 10 and older with type 2 diabetes. Zepbound is approved for weight management in adults with obesity (a BMI of 30 or higher) or those with a BMI of 27 or higher who also have at least one weight-related health condition such as high blood pressure, high cholesterol, or heart disease.
How Tirzepatide Works
Tirzepatide activates two hormone receptors at once: GIP and GLP-1. Most older medications in this class only target GLP-1. By engaging both pathways simultaneously, tirzepatide triggers stronger insulin release when blood sugar is elevated, improves how fat tissue functions, and sends more potent appetite-suppressing signals to the brain. This dual action is why the drug performs well for both blood sugar control and weight loss.
Notably, tirzepatide leans more heavily on the GIP receptor than the GLP-1 receptor. Research published in JCI Insight found this “imbalanced” design actually enhances insulin secretion while still delivering the appetite reduction that GLP-1 drugs are known for. The combination produces metabolic effects that go beyond what either pathway achieves alone.
What the Clinical Trials Show
For diabetes, the results are striking. In the SURPASS-1 trial, the highest dose of tirzepatide lowered A1C by about 2 percentage points. Over half of participants on that dose reached an A1C below 5.7%, which is the range typically seen in people without diabetes. Across all doses, roughly 82% to 92% of participants hit the standard treatment target of A1C below 7%. No cases of dangerously low blood sugar were observed.
For weight loss, tirzepatide is equally impressive. In a 72-week clinical trial, participants taking the drug lost about 50 pounds on average, representing roughly 20% of their body weight. Nearly one-third of participants lost at least 25% of their starting weight. A head-to-head trial against semaglutide (the active ingredient in Wegovy) found that tirzepatide produced greater weight loss over the same timeframe.
Side Effects Are Identical
Because the medication is chemically the same, the side effect profile doesn’t change based on which brand name is on the box. The most common issues are gastrointestinal: nausea, diarrhea, constipation, stomach discomfort, and acid reflux. These tend to be worst during the initial weeks and when the dose increases, then gradually improve as your body adjusts.
Less common but more serious reactions include difficulty swallowing, skin rash or redness, vomiting, and swelling of the face or throat. Stomach pain and heartburn fall somewhere in between, reported frequently enough to be worth knowing about but not experienced by the majority of users.
Why the Brand Name Matters for Cost
Even though the drug inside is identical, your insurance coverage and out-of-pocket cost can differ dramatically depending on which brand is prescribed. Insurance plans often cover Mounjaro under their diabetes formulary and Zepbound under a separate weight management category, if they cover weight loss medications at all. Some plans cover one but not the other.
Eli Lilly offers a savings card program for Mounjaro that can bring the cost down to as little as $25 for a one-month or three-month supply if you have commercial insurance. Zepbound has its own savings program with similar structure. Neither program covers people on government insurance like Medicare or Medicaid. Without insurance or a savings card, both medications carry the same high list price since they’re the same drug at the same doses.
Can You Switch Between Them?
If you’re taking Mounjaro for diabetes and also want the weight management benefits, you’re already getting them. Tirzepatide reduces weight regardless of which label it’s sold under. However, your prescription is tied to the specific FDA-approved indication. A doctor prescribes Mounjaro when the primary goal is blood sugar control and Zepbound when the primary goal is weight loss. Switching brands could affect your insurance coverage, your copay, or your eligibility for savings programs, so it’s worth checking with your plan before making any changes.
The practical takeaway is simple: Mounjaro and Zepbound deliver the exact same molecule at the same doses through the same type of injection pen. The only differences are the condition listed on the label, the color of the packaging, and how your insurance categorizes the prescription.